<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210620051635N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-30</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Antimicrobial efficacy of  combination of chlorhexidine and nano-silver fluoride mouthwashes on orthodontic patients</public_title>
      <acronym></acronym>
      <scientific_title>The antimicrobial efficacy of combination of chlorhexidine and nano-silver fluoride mouthwashes on Streptococcus  mutans in orthodontic patients (Randomized clinical trial)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56988</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: In order to assign patients to the study groups, permuted block randomization method was used with three patients in each block.The created list is as follows:

ACB  ABC  BAC  ABC  BCA  BAC  CAB  BCA  CAB  ACB    ABC   CBA   CAB   CBA ACB

The results will be reported by mean ± standard deviation and frequency percentage. Shapiro-Wilk test will be used to analyze the normality of the data. In order to compare the amount of bacteria in the study groups, analysis of variance of covariance will be used. A probability of less than 5% will be considered a significant level. For data analysis, SPSS software version 20 will be used, Blinding description: This double-blind study is a randomized clinical study designed to evaluate the effectiveness of 3 mouthwashes and will be performed during 14 days in the orthodontic department of Tabriz Dental School. From the patients who refer to the orthodontic department, 45 people who meet the inclusion criteria will be selected and they will be asked to fill out the written consent form.
Random allocation software will be used for randomization and allocation. Each eligible patient will be assigned to one of the three study groups, based on the list kept by the head of the faculty. Patients will receive their mouthwashes according to the letters of each block: A: Chlorhexidine  B:Silver fluoride nano-particles  C: Combined nano-silver fluoride and Chlorhexidine mouthwash

ACB ABC BAC ABC BCA BAC CAB BCA CAB ACB ABC CBA CAB CBA ACB

Patients will be randomly assigned to three groups.

Group 1 (n = 15): Chlorhexidine mouthwash 0.2%
Group 2 (n = 15): Silver fluoride nano-particles mouthwash 0.04%
Group 3 (n = 15): Mouthwash containing a mixture of 0.1% chlorhexidine and silver fluoride nano-particles (400 ppm)
For this purpose, mouthwash will be poured into similar plastic containers with the same size. The patient and the researcher will not be aware of the type of mouthwash.</study_design>
      <phase>2</phase>
      <hc_freetext>dental caries in orthodontic patients.</hc_freetext>
      <i_freetext>The first group (n = 15): Chlorhexidine mouthwash 0.2% , The second group (n = 15): Silver fluoride mouthwash 0.04% ,The third group (n = 15): Mouthwash containing 0.1% chlorhexidine mixture and silver fluoride nanoparticles (400 ppm)                                                                           All patients will be asked to brush their teeth with regular toothpaste twice a day for 2-4 minutes and to rinse their mouth with 10 ml of mouthwash twice a day for 30 seconds and not to eat or drink anything for half an hour after that.The best time to use mouthwashes is before bed and after brushing..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
----

When:
6 months after the results are published

To whom:
researchers of academic and scientific institutions

Conditions:
-----

Where to obtain:
----

How to obtain:
-----

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>amir hooman sadr haghighi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>15th floor, Azerbaijan Tower, 17 Shahrivar Jadid Ave Tabriz</address>
        <city>tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>0</zip>
        <telephone>+98 41 3557 2636</telephone>
        <email>Hooman_sadr7@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>amir hooman sadr haghighi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>15th floor, Azerbaijan Tower, 17 Shahrivar Jadid Ave Tabriz</address>
        <city>tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>0</zip>
        <telephone>+98 41 3557 2636</telephone>
        <email>Hooman_sadr7@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients not receiving antibiotic therapy for the past three weeks
Patients not receiving fluoride therapy for the past three weeks
patients agreed with the informed written consent previous to the study
Patients in the 20-40 age range</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with dental prostheses (crown and bridge)
Patients with soft tissue pathology
Patients with poor oral health (DMFT&gt; 8)
Smokers
Patients with orthodontic removable appliances</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first group (n = 15): Chlorhexidine mouthwash 0.2% , The second group (n = 15): Silver fluoride mouthwash 0.04% ,The third group (n = 15): Mouthwash containing 0.1% chlorhexidine mixture and silver fluoride nanoparticles (400 ppm)                                                                           All patients will be asked to brush their teeth with regular toothpaste twice a day for 2-4 minutes and to rinse their mouth with 10 ml of mouthwash twice a day for 30 seconds and not to eat or drink anything for half an hour after that.The best time to use mouthwashes is before bed and after brushing.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Time،The amount of bacteria،Studied groups. Timepoint: Before intervention - 14 days after the intervention (Using Mouthwash). Method of measurement: Time: 2 times (before and after using mouthwash (first day and 14th))                                                                                                        Bacterial content: Colony counting unit                                                                  study groups: Chlorhexidine, silver fluoride, combination of Chlorhexidine and silver fluoride.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Time, The amount of bacteria, Study groups. Timepoint: 2 times  (before intervention and 14 days after intervention). Method of measurement: Time: 2 times (before intervention _ 14 days after intervention) Bacterial content: colony-forming unit Study groups: 2 times (before intervention _14 days after intervention).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-05-22</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>no10، narges alley، baghe esmail agha ave، tohid blvd mahabad West Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
